Abbott Laboratories (ABT) Non-Current Assets (2009 - 2026)
Abbott Laboratories (ABT) posted Non-Current Assets of $84.7 billion for Q2 2026, little changed sequentially from $84.9 billion in Q1 2026, and up 42.28% YoY from $59.5 billion in Q2 2025.
Abbott Laboratories (ABT) Non-Current Assets (2009 - 2026) Analysis & Trends
Abbott Laboratories has reported Non-Current Assets for 18 years, with the latest figure at $84.7 billion in Q2 2026.
- Quarterly Non-Current Assets rose 42.28% year-over-year to $84.7 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $289.7 billion (up 28.1% YoY) and the FY2025 annual result came in at $60.7 billion, up 5.12% from the prior year.
- Non-Current Assets steadied at $84.7 billion in Q2 2026 per ABT's latest filing, from $84.9 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $84.9 billion in Q1 2026 and troughed at -$2.9 billion in Q4 2022.
- A 5-year average of $53.3 billion and a median of $50.5 billion in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets decreased 4.67% in 2022, then soared 1850.74% in 2023.
- Over 5 years, Non-Current Assets stood at -$2.9 billion in 2022, then jumped by 1850.74% to $50.5 billion in 2023, then grew by 14.27% to $57.8 billion in 2024, then rose by 5.12% to $60.7 billion in 2025, then soared by 39.5% to $84.7 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $84.7 billion, $84.9 billion, and $60.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.24 Bn | 193.64 Bn | 7.27 Bn | 84.70 Bn |
| 2 | Stryker | 128.63 Bn | 125.15 Bn | 4.50 Bn | 33.51 Bn |
| 3 | Medtronic | 119.19 Bn | 109.97 Bn | 6.41 Bn | 68.24 Bn |
| 4 | Boston Scientific | 73.51 Bn | 72.97 Bn | 3.85 Bn | 37.24 Bn |
| 5 | Edwards Lifesciences | 52.11 Bn | 47.85 Bn | 1.35 Bn | 7.05 Bn |
| 6 | Dexcom | 34.64 Bn | 32.70 Bn | 830.00 Mn | 2.37 Bn |
| 7 | GE HealthCare Technologies | 34.01 Bn | 31.90 Bn | 2.18 Bn | 26.75 Bn |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 20.19 Bn |
| 9 | Steris | 23.14 Bn | 22.65 Bn | 684.20 Mn | 8.29 Bn |
| 10 | Zimmer Biomet Holdings | 19.32 Bn | 18.91 Bn | 1.54 Bn | 17.70 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.70 Bn |
| Mar 31, 2026 | 84.92 Bn |
| Dec 31, 2025 | 60.72 Bn |
| Sep 30, 2025 | 59.34 Bn |
| Jun 30, 2025 | 59.53 Bn |
| Mar 31, 2025 | 58.30 Bn |
| Dec 31, 2024 | 57.76 Bn |
| Sep 30, 2024 | 50.55 Bn |
| Jun 30, 2024 | 49.90 Bn |
| Mar 31, 2024 | 50.09 Bn |
| Dec 31, 2023 | 50.54 Bn |
| Sep 30, 2023 | 49.43 Bn |
| Jun 30, 2023 | 49.85 Bn |
| Mar 31, 2023 | 49.42 Bn |
| Dec 31, 2022 | -2.89 Bn |
| Sep 30, 2022 | 47.96 Bn |
| Jun 30, 2022 | 49.25 Bn |
| Mar 31, 2022 | 50.58 Bn |
| Dec 31, 2021 | -3.07 Bn |
| Sep 30, 2021 | 50.30 Bn |